comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-03 03:18:10 - browse：67

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Novel spinal cord stimulator treats paralysis without surgery

WSS

Black vets could get higher VA benefits if race not used in lung test

Why sickle cell disease is getting the first CRISPR treatment

As billionaires fund anti

SCOTUS to consider access to abortion pill mifepristone

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

AltruBio raises $225 million to develop ulcerative colitis drug

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

At least 13 dead in Texas as scorching temps continue

AI for drug discovery: Experts on separating hype from reality

In age of alternative facts, a scholarly course on calling out crap

Why sickle cell disease is getting the first CRISPR treatment

Virginia high school admissions case could be legal follow

SCOTUS to consider access to abortion pill mifepristone

United colonoscopy coverage change 'may cost lives,' doctors say

SCOTUS to consider access to abortion pill mifepristone

Supreme Court strikes down use of affirmative action

The creative science of coining drug names

hotspot

Empower primary care with adequate payments and technology

BIO to announce reorganization, senior leaders expected to depart

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

AI models in health care face new federal disclosure requirements

PBM executives asked to testify by House panel

What causes an itch? Researchers may have solved the mystery

explore

entertainment

focus

focus